| ISUP>2 | ISUP>3 | ||||||
|---|---|---|---|---|---|---|---|
| *Intervals in parenthesis are 95% CI. The absolute added value of a given biopsy technique is defined by the percentage of patients of the entire cohort diagnosed only by this biopsy technique. ISUP = International Society of Urological Pathology (grade); MRI-TBx = magnetic resonance imaging-targeted biopsies; ND = not defined. |
|||||||
| ISUP grade | Cochrane meta-analysis* «Drost FH, Osses DF, Nieboer D, ym. Prostate MRI, w...»1 | MRI-FIRST trial* «Rouvière O, Puech P, Renard-Penna R, ym. Use of pr...»2 | 4M trial «van der Leest M, Cornel E, Israël B, ym. Head-to-h...»3 | Cochrane meta-analysis* «Drost FH, Osses DF, Nieboer D, ym. Prostate MRI, w...»1 | MRI-FIRST trial* «Rouvière O, Puech P, Renard-Penna R, ym. Use of pr...»2 | 4M trial «van der Leest M, Cornel E, Israël B, ym. Head-to-h...»3 | |
| Biopsy-naïve | Added value of MRI-TBx | 6.3% (4.8–8.2) |
7.6% (4.6–11.6) |
7.0% (ND) | 4.7% (3.5–6.3) |
6.0% (3.4–9.7) |
3.2% (ND) |
| Added value of systematic biopsy | 4.3% (2.6–6.9) |
5.2% (2.8–8.7) |
5.0% (ND) | 2.8% (1.7–4.8) |
1.2% (0.2–3.5) |
4.1% (ND) | |
| Overall prevalence | 27.7% (23.7–32.6) | 37.5% (31.4–43.8) | 30% (ND) | 15.5% (12.6–19.5) | 21.1% (16.2–26.7) | 15% (ND) | |
| Prior negative biopsy | Added value of MRI-TBx | 9.6% (7.7–11.8) |
- | - | 6.3% (5.2–7.7) |
- | - |
| Added value of systematic biopsy |
2.3% (1.2–4.5) |
- | - | 1.1% (0.5–2.6) |
- | - | |
| Overall prevalence | 22.8% (20.0–26.2) | - | - | 12.6% (10.5–15.6) | - | - | |